Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Bemnifosbuvir (BEM, AT-527), a novel nucleotide analogue inhibitor of the hepatitis C virus NS5B polymerase.

Expert opinion on investigational drugs - 1 Jan 2024

Zhou Xiao-Jian, Good Steven S, Pietropaolo Keith, Huang Qi, Moussa Adel, Hammond Janet Mj, Sommadossi Jean-Pierre

Abstract excerpt

INTRODUCTION: Chronic hepatitis C virus (HCV) persists as a public health concern worldwide. Consequently, optimizing HCV therapy remains an important objective. While current therapies are generally highly effective, advanced antiviral agents are needed to maximize cure rates with potentially shorter treatment durations in a broader patient population, particularly those patients with advanced diseases who...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Drug Therapy, Combination

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genotype

Share to Hepacivirus

Share to Hepatitis C

Share to Hepatitis C, Chronic

Share to Sofosbuvir

Share to Viral Nonstructural Proteins

Source

Identifiers

PMID: 38265202
DOI: 10.1080/13543784.2024.2305137

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Bemnifosbuvir (BEM, AT-527), a novel nucleotide analogue inhibitor of the hepatitis C virus NS5B polymerase.PMID 38265202Read ↗

Nucleoside Inhibitors of Hepatitis C Virus NS5B Polymerase: A Systematic Review.Semantic proximity Read ↗

Hepatitis C therapy with HCV NS5B polymerase inhibitors.Semantic proximity Read ↗

Sofosbuvir, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infectionSemantic proximity Read ↗

Investigational nucleoside and nucleotide polymerase inhibitors and their use in treating hepatitis C virusSemantic proximity Read ↗

Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights.Semantic proximity Read ↗

Sofosbuvir (GS-7977), a pan-genotype, direct-acting antiviral for hepatitis C virus infection.Semantic proximity Read ↗

Beclabuvir for the treatment of hepatitis C.Semantic proximity Read ↗

Preclinical characterization of GS-9669, a thumb site II inhibitor of the hepatitis C virus NS5B polymerase.Semantic proximity Read ↗

Targeting NS5B RNA-dependent RNA polymerase for anti-HCV chemotherapy.Semantic proximity Read ↗

Discovery of Novel Nucleotide Prodrugs with Improved Potency Against HCV Variants Carrying NS5B S282T Mutation.Semantic proximity Read ↗

Randomized, placebo-controlled, single-ascending-dose study of BMS-791325, a hepatitis C virus (HCV) NS5B polymerase inhibitor, in HCV genotype 1 infection.Semantic proximity Read ↗

Dual sofosbuvir and ribavirin therapy for chronic hepatitis C infection.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.